Comparative study of two vaccination schedules for the subunit Herpes Zoster vaccine in Multiple Sclerosis and Neuromyelitis optica spectrum disease patients treated with anti-CD20 therapy: an open-label randomised controlled trial.
Shingles is an infection caused by the chickenpox virus that leads to a painful, blistering rash. People with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) who take therapies like rituximab or ocrelizumab have a higher risk of shingles. This is because these medicines lower certain immune defences. A vaccine called Shingrix helps protect against shingles and is given in two separate doses. However, doctors want to know which schedule works best for people on these treatments. This study tests two options: getting the second injection two months after the first, or waiting six months. Over 13 months, researchers will test participants' blood to see which schedule produces more protective antibodies and immune cells. The results will help doctors offer the best possible protection to people living with MS and NMOSD.
At a glance
What is this study about?
Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) are long-term conditions affecting the central nervous system, including the brain and spinal cord. Many people manage their condition with treatments called anti-CD20 therapies, such as rituximab or ocrelizumab. These treatments work well because they reduce overactive immune cells that damage nerves. However, dampening these cells can also make it harder for the body to fight off infections, including shingles.
Shingles occurs when the virus that causes chickenpox wakes up again later in life, causing a painful rash and sometimes lasting nerve pain. A vaccine called Shingrix helps train the immune system to fight off the virus. It is given as two separate injections, usually spaced between two and six months apart. Because anti-CD20 medicines change how the immune system works, it is not yet clear whether a shorter gap or a longer gap between jabs provides better, longer-lasting immunity.
In this study, researchers will compare both schedules directly. Participants will be placed into one of two groups to receive their second vaccine dose at either two months or six months. By measuring the levels of antibodies and immune cells in blood samples over 13 months, doctors hope to find the most effective schedule to keep patients protected.
Key takeaways
- The trial tests whether a 2-month or 6-month gap between shingles vaccine doses works best.
- It is for adults with MS or NMOSD who are treated with rituximab or ocrelizumab.
- Participants receive two doses of the Shingrix vaccine and attend regular blood tests over 13 months.
- Shingrix is a non-live vaccine and cannot cause a shingles infection.
- Taking part is completely voluntary and will not replace or delay your regular treatment.
Who may be eligible?
This study is open to adults aged 18 and over who have been diagnosed with either multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD). To be eligible, you must currently be receiving an anti-CD20 medicine, such as rituximab or ocrelizumab, to manage your condition.
Because the study focuses on how your body responds to the vaccine, you must be able to attend regular clinic visits for blood tests and injections over roughly 13 months. Men and women of all backgrounds are welcome to take part.
You may not be able to join if you have already had the Shingrix vaccine recently, if you have had severe allergic reactions to vaccines in the past, or if you have other medical issues that could make taking part unsafe. The study doctor will check your medical records to confirm whether the study is suitable for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with MS or NMOSD.
- I am currently treated with rituximab or ocrelizumab.
- I have not recently received the Shingrix shingles vaccine.
- I am able to attend clinic visits and give blood samples over a 13-month period.
What does participation involve?
If you take part, your participation will last about 13 months. You will receive two doses of the Shingrix vaccine, given as an injection into the muscle of your upper arm. A computer will randomly decide whether you get your second dose two months or six months after the first dose. You will visit the clinic for routine health checks and blood tests. Blood samples are taken before each jab, one month after your second jab, and around the time of your regular MS or NMOSD treatment infusions at months 7 and 13. The study team will track your health throughout and check for any side effects.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
Can the Shingrix vaccine give me shingles?
No. Shingrix is a non-live vaccine, meaning it contains only a small part of the virus rather than the live virus itself. It cannot cause shingles or chickenpox.
Will taking part disrupt my regular MS or NMOSD treatment?
No. The study visits and blood tests are designed to work alongside your normal treatment schedule with rituximab or ocrelizumab.
Do I have to pay to join the trial?
No. In the UK, you do not pay for trial vaccines or tests. You may also be offered help with travel expenses to attend your study visits.
Can I choose whether I wait two or six months for my second jab?
No. A computer assigns you to the two-month or six-month group by chance. This ensures the trial results are completely fair and unbiased.
What happens if I decide I want to stop taking part?
You are free to leave the trial at any point without giving a reason. Your standard medical treatment and relationship with your doctors will stay the same.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.